Development of osteonecrosis and improved survival in B-ALL: results of Children’s Oncology Group Trial AALL0232
- 7 December 2023
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 38 (2) , 258-265
Abstract
Osteonecrosis is a significant toxicity of acute lymphoblastic leukemia (ALL) therapy. In retrospective analyses, superior event-free survival was noted among affected adolescents in an earlier trial. We prospectively assessed osteonecrosis incidence, characteristics, and risk factors in patients 1–30 years with newly diagnosed high-risk B-ALL on COG AALL0232. Patients were randomized to induction dexamethasone vs prednisone, and interim maintenance high-dose methotrexate vs escalating-dose Capizzi methotrexate/pegaspargase. Event-free and overall survival were compared between patients with/without imaging-confirmed osteonecrosis. Osteonecrosis developed in 322/2730 eligible, evaluable patients. The 5-year cumulative incidence was 12.2%. Risk was greater in patients ≥10 years (hazard ratio [HR], 7.23; P < 0.0001), particularly females (HR, 1.37; P = 0.0057), but lower in those with asparaginase allergy (HR, 0.60; P = 0.0077). Among rapid early responders ≥10 years, risk was greater with dexamethasone (HR, 1.84; P = 0.0003) and with prednisone/Capizzi (HR, 1.45; P = 0.044), even though neither therapy was independently associated with improved survival. Patients with osteonecrosis had higher 5-year event-free (HR, 0.51; P < 0.0001) and overall survival (HR, 0.42; P < 0.0001), and this was directly attributable to reduced relapse rates (HR, 0.57; P = 0.0014). Osteonecrosis in high-risk B-ALL patients is associated with improved survival, suggesting an important role for host factors in mediating both toxicity and enhanced efficacy of specific therapies.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (U10 CA098543, U10 CA180886, U10 CA098413, U10 CA180899)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
This publication has 40 references indexed in Scilit:
- Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemiaLeukemia, 2012
- Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemiaBlood, 2011
- Glucocorticoid use in acute lymphoblastic leukaemiaThe Lancet Oncology, 2010
- Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase HypersensitivityClinical Pharmacology & Therapeutics, 2010
- A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology GroupBlood, 2008
- Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology GroupBlood, 2008
- High Body Mass Index Increases the Risk for Osteonecrosis in Children With Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2007
- Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With LeukemiaJournal of Clinical Oncology, 2004
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958